ABT stock forecast, quote, news & analysis

Key Takeaways

• ABT surged approximately +13.9% over the past 30 days, rallying from $88.41 on June 18 to $100.68 on July 17, driven primarily by a strong Q2 2026 earnings beat and upwardly revised full-year EPS guidance.
• Q2 adjusted EPS of $1.31 surpassed consensus estimates of $1.28, while total revenue of $12.59 billion rose 13% year-over-year on a reported basis.
• Management raised full-year 2026 adjusted EPS guidance to $5.45–$5.60, up from the prior range of $5.38–$5.58, and reaffirmed comparable sales growth guidance of 6.5%–7.5%.
• The Exact Sciences acquisition, completed in March 2026, fueled a 42.3% reported surge in Diagnostics revenue, with Cologuard posting mid-teens comparable growth in the Cancer Diagnostics unit.
• Medical Devices delivered 8.5% comparable sales growth, with Electrophysiology in the low teens and Diabetes Care CGM sales exceeding $2 billion.
• Multiple analyst price targets were raised following the report, including BTIG to $134 and Wells Fargo to $112, reflecting improved conviction in the second-half outlook.

Abbott Laboratories (ABT) Company Overview and Market Position

Abbott Laboratories is a diversified global healthcare company headquartered in Abbott Park, Illinois. Founded in 1888, the company operates across four major business segments: Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals. Abbott is best known for market-leading products such as the FreeStyle Libre continuous glucose monitoring (CGM) system, the Ensure and Pedialyte nutrition franchises, the Alinity family of diagnostic instruments, and a growing portfolio of cardiovascular devices including the AVEIR leadless pacemaker and Volt pulsed field ablation catheter. With a market capitalization exceeding $170 billion and operations in more than 160 countries, Abbott holds a defensive yet growth-oriented position in healthcare. Investors follow the stock closely for its balanced exposure to medtech innovation, stable diagnostics demand, and a 54-year track record of consecutive annual dividend increases.

Abbott Laboratories (ABT) Stock Price Performance: Last 30 Days vs. Quarter

Over the 30-day period ending July 17, 2026, ABT rallied approximately +13.9%, climbing from a closing price of $88.41 on June 18 to $100.68. The bulk of the move occurred in a two-day burst following the company's Q2 earnings release on July 16, when shares jumped from $89.27 to $98.83 in a single session — the stock's best single-day performance in years — before adding further gains the next day.

Zooming out to the full quarter, the stock's trajectory tells a more complex story. In early April, ABT traded near $103 before a sharp sell-off driven by concerns over the Exact Sciences integration, Nutrition segment headwinds, and broader macroeconomic uncertainty. The stock bottomed at $82.56 on May 11 before gradually recovering through June as sentiment improved around the acquisition and demand indicators stabilized. By quarter-end, ABT had clawed back to roughly $100, reflecting a modest quarterly gain but a pronounced V-shaped recovery from mid-spring lows.

What Drove ABT Stock Price in the Last 30 Days

The primary catalyst behind the 30-day surge was Abbott's Q2 2026 earnings report on July 16, which exceeded Wall Street expectations on both the top and bottom lines. Adjusted earnings per share of $1.31 beat the consensus estimate of $1.28, while reported revenue of $12.59 billion topped the $12.48 billion analyst forecast. Comparable sales grew 4.8%, marking an acceleration from the prior two quarters and validating management's thesis that growth momentum was building across the portfolio.

Equally important was the guidance raise. Abbott lifted its full-year 2026 adjusted EPS range to $5.45–$5.60 from $5.38–$5.58, signaling confidence in margin expansion and second-half acceleration. CEO Robert Ford emphasized that approximately 80% of the expected second-half growth lift would come from four areas: Nutrition, Electrophysiology, Core Laboratory, and Cancer Diagnostics. The Nutrition business, which had been a drag on sentiment for several quarters, showed sequential improvement of $125 million, while international pediatric nutrition returned to positive growth at 6.5%.

The Exact Sciences acquisition also proved to be a tailwind rather than the overhang many investors had feared. Cancer Diagnostics posted 13.3% comparable growth, with Cologuard delivering mid-teens gains fueled by new and repeat users. The American Cancer Society's May 2026 reaffirmation of Cologuard and Cologuard Plus as preferred colorectal cancer screening options further reinforced the segment's long-term outlook. Meanwhile, Medical Devices grew 8.5% on a comparable basis, led by low-teens Electrophysiology growth and 9.5% growth in Diabetes Care, where CGM sales surpassed $2 billion for the quarter.

Analyst reaction was swift and broadly positive. BTIG Research raised its price target to $134 from $131, Wells Fargo lifted its target to $112 from $109, and several other firms reiterated Buy or Outperform ratings. The earnings beat, coupled with management's assertive tone on the conference call, effectively reset market expectations and triggered the sharpest two-day rally ABT had experienced in years.

What Drove ABT Stock Performance Over the Last Quarter

Abbott's quarterly performance was defined by a deep sell-off and subsequent recovery. The stock entered the second quarter under significant pressure, having fallen from roughly $103 in early April to a multi-month low of $82.56 by May 11. Several factors contributed to the decline: uncertainty around the $23 billion Exact Sciences acquisition, which closed in March and temporarily compressed margins; a challenging Nutrition segment that posted a 6% reported sales decline in Q1; and broader fears that potential Medicaid disenrollment and ACA subsidy changes could soften medical device procedure volumes.

The recovery began in late May and gained momentum through June as Abbott provided incremental evidence that the Exact Sciences integration was progressing smoothly and that Nutrition trends were stabilizing. The April completion of patient enrollment in the TECTONIC coronary IVL pivotal trial, the May CE Mark approval for Libre Duo — the world's first dual glucose-ketone wearable sensor — and strong data presentations at the Heart Rhythm Society conference all reinforced the narrative that Abbott's pipeline remained robust. By the time Q2 earnings landed in mid-July, the stock had already recovered much of its spring losses, and the decisive beat-and-raise quarter provided the final catalyst that pushed shares back toward the $100 level.

Trending AI Robots

For investors seeking a data-driven edge in navigating stocks like Abbott Laboratories, Tickeron offers a curated selection of Trending AI Robots. Tickeron's platform features hundreds of AI-powered trading bots that collectively trade thousands of tickers, but only the most relevant and top-performing bots appear in this dedicated section. These bots employ a range of strategies — from short-term swing trading to longer-duration trend-following — and cover diverse timeframes, risk profiles, and performance metrics. The Trending AI Robots page is designed to help traders quickly identify the strategies that are currently generating the strongest signals in real market conditions. Whether you are exploring automated trading for the first time or refining an existing approach, the page provides a transparent window into which AI-driven strategies are resonating with today's market dynamics.

ABT Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, several factors will shape ABT's trajectory. The most immediate is execution against the second-half acceleration that management forecast. Third-quarter adjusted EPS guidance of $1.38–$1.46 sets a higher bar, and investors will closely monitor whether Nutrition's recovery, Electrophysiology's Volt 2.0 ramp, and Cancer Diagnostics' Cologuard momentum deliver as promised. The international rollout of Libre Duo in the fall and the anticipated U.S. launches of Amulet 360, coronary IVL, and TactiFlex Duo over the next twelve months represent significant pipeline catalysts that could sustain the growth narrative.

On the macroeconomic front, any signs of weakening hospital procedure volumes or shifts in insurance coverage related to Medicaid or ACA policy changes remain risks to monitor. Competitive intensity in the U.S. mitral valve space and the impact of China's volume-based procurement program on the Established Pharmaceuticals segment are additional headwinds worth watching. Conversely, expanded CGM reimbursement for non-insulin Type 2 diabetes patients — a decision that could unlock approximately 10 million Medicare beneficiaries — represents a potentially transformative catalyst that, while uncertain in timing, would meaningfully alter the growth trajectory of Abbott's largest device franchise.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations